4.3 Review

Corticosteroid injection treatment for dactylitis in psoriatic arthritis

出版社

SAGE PUBLICATIONS LTD
DOI: 10.1177/1759720X211041864

关键词

corticosteroid; dactylitis; injection; psoriatic arthritis; tenosynovitis; therapy; treatment; ultrasound

向作者/读者索取更多资源

Dactylitis is a common clinical feature in 30-50% of psoriatic arthritis (PsA) patients, serving as a marker for disease severity, independent predictor of cardiovascular morbidity, and impairing motor functions. Current treatment strategies primarily involve corticosteroid injections, with a lack of evidence from randomized controlled trials specifically targeting dactylitis as a primary endpoint.
Dactylitis - a hallmark clinical feature of psoriatic arthritis (PsA) - that occurs in 30-50% of PsA patients, is a marker of disease severity for PsA progression, an independent predictor of cardiovascular morbidity and impairs the motor functions of PsA patients. There is a paucity of evidence for the treatment due to the absence of randomized controlled trials assessing dactylitis as a primary endpoint and current practice arises from the analysis of dactylitis as a secondary outcome. Corticosteroid (CS) injections for dactylitis in PsA patients are a therapeutic treatment option for patients with isolated dactylitis or for patients with flares in tendon sheaths, despite stable and effective systemic treatment. The aim of this narrative review is to briefly illustrate the clinical aspects of dactylitis in PsA, the imaging and clinimetric tools used to diagnose and monitor dactylitis, the current treatment strategies and principally to provide a comprehensive picture of the clinical efficacy and safety with ultrasound-guide and blind techniques of CS injections for dactylitis in PsA patients.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据